UBS Group’s 4D Pharma PLC LBPS Stock Holding History

UBS Group’s Portfolio LBPS Stock Details LBPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,155	Closed	-$10K	–	11621
2022 Q1	$10K	Buy	2,155 +1,243	+136%	+$5.19K	﹤0.01%	8510
2021 Q4	$5K	Hold	912	–	–	﹤0.01%	9477
2021 Q3	$6K	Hold	912	–	–	﹤0.01%	8493
2021 Q2	$10K	Hold	912	–	–	﹤0.01%	8097
2021 Q1	$11K	Buy	+912	New	+$11.4K	﹤0.01%	7889

Other funds holding LBPS

Ruffer LLP London, United Kingdom $2.44B AUM 44.75% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

UBS Group's LBPS Position: Q2 2022 in Review

UBS Group sold out of 4D Pharma PLC (LBPS) in Q2 2022, closing a stake of 2,155 shares — an estimated $10K sold.

UBS Group first reported a position in LBPS in Q1 2021 and held it in 5 quarters. The position peaked at $11K in Q1 2021. 8 funds tracked by Wall St. Rank hold LBPS as of Q2 2022.

UBS Group reported no remaining 4D Pharma PLC position as of Q2 2022 after selling out during the quarter.
UBS Group sold 2,155 4D Pharma PLC shares in Q2 2022, an estimated $10K.
UBS Group first reported a position in 4D Pharma PLC in Q1 2021 and held it in 5 quarters.
UBS Group's 4D Pharma PLC position peaked at $11K in Q1 2021.
8 funds tracked by Wall St. Rank held 4D Pharma PLC as of Q2 2022.

Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.